Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memantine for the treatment of negative symptomatology and cognitive impairment in schizophrenia.

Trial Profile

Memantine for the treatment of negative symptomatology and cognitive impairment in schizophrenia.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2013

At a glance

  • Drugs Memantine (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Oct 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 10 Feb 2012 Planned end date changed from 1 Jul 2010 to 1 Jul 2012 as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Planned end date changed from 1 Jul 2009 to 1 Jul 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top